8-K filing — INCYTE CORP (INCY)
Filed: 2026-11-13 AccNo: 0000879169-26-000068 Size: 135 KB Item 8.01: Other Events
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-13 AccNo: 0000879169-26-000068 Size: 135 KB Item 8.01: Other Events
CNBC traders picked Micron, Digital Realty, Natera and Moody’s; Natera raised FY2026 sales guidance after strong results, while Moody’s missed estimates.
Natera and Incyte have entered into a clinical collaboration agreement to evaluate Incyte's investigational bispecific immunotherapy, INCA33890, in a new Phase II study for patients with stage 2/3 colorectal cancer.
Natera, Inc. has entered into a clinical collaboration agreement with Incyte to evaluate the investigational bispecific immunotherapy INCA33890 in a new Phase II study for colorectal cancer patients.
Analyst Max Masucci of Roth MKM maintained a 'Buy' rating on Natera, Inc. while adjusting the price target to $405.
Baird analyst Catherine Ramsey Schulte maintained a Buy rating on Natera, Inc. and increased the price target to $403.